May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Inhibition of Ras/Raf/MEK/MAPK Pathway by dbcAMP in Rat Lacrimal Gland
Author Affiliations & Notes
  • C. Funaki
    Schepens Eye Research Inst/Dept of Opthal, Harvard Medical School, Boston, Massachusetts
    Department of Opthalmology, Tokyo Women's Medical University, Tokyo, Japan
  • R. R. Hodges
    Schepens Eye Research Inst/Dept of Opthal, Harvard Medical School, Boston, Massachusetts
  • D. A. Dartt
    Schepens Eye Research Inst/Dept of Opthal, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  C. Funaki, None; R.R. Hodges, None; D.A. Dartt, None.
  • Footnotes
    Support  NIH Grant EY06177
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5301. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Funaki, R. R. Hodges, D. A. Dartt; Inhibition of Ras/Raf/MEK/MAPK Pathway by dbcAMP in Rat Lacrimal Gland. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5301. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We previously showed that increasing intracellular cyclic AMP (cAMP) inhibited both basal and stimulated p42/p44 mitogen-activated protein kinase (MAPK, ERK1/2) by the agonists carbachol (a cholinergic agonist, Cch), phenylephrine (an alpha1D adrenergic agonist, Ph) and EGF (epidermal growth factor). Activation of this pathway accounts for the potentiation of lacrimal gland protein secretion. In this study we determine which step in the Ras/Raf/MEK/MAPK pathway cyclic AMP inhibits.

Methods: : Exorbital lacrimal glands were removed from male Sprague-Dawley rats. Acini were isolated by collagenase digestion. Cellular cAMP levels were increased by using the cell permeant cAMP analogs, dibutyryl cAMP (dbcAMP) for 0-30 min. In addition, acini were preincubated with or without dbcAMP (10-3M) for 30 min prior to stimulation for 5 min with Cch (10-4M), Ph (10-4M) or EGF (10-7M). Acini were homogenized and western blot analysis was performed using antibodies specific to phosphorylated (activated) p42/44 MAPK, total p42-MAPK, phosphorylated Raf-1(ser338), total Raf-1, phosphorylated MEK, total MEK, phosphorylated EGF receptor and total EGF receptor. Ras activity was measured by using Ras activation kit.

Results: : DbcAMP (10-3M) significantly inhibited basal MEK (at 30 min) and MAPK at all times and agonist (Cch, Ph and EGF)-stimulated MAPK activity. However dbcAMP did not inhibit basal phosphorylation of EGF receptor or Ras and Raf-1 activity at any time point. Agonist (Cch, Ph and EGF)-stimulated Raf-1 and MEK activity was inhibited by dbcAMP, although not significantly.

Conclusions: : dbcAMP inhibits basal MAPK activity either directly or upstream of MEK but downstream of Raf-1. In turn, agonist-stimulated MAPK pathway could be inhibited by dbcAMP directly at MAPK and potentially at Ras activation of Raf-1.

Keywords: lacrimal gland • signal transduction • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×